Overview

The Effect of Erythropoietin on Alveolar Fluid Clearance in Patients With Acute Respiratory Distress Syndrome

Status:
Recruiting
Trial end date:
2027-03-31
Target enrollment:
0
Participant gender:
All
Summary
Acute respiratory distress syndrome (ARDS) is a common acute and critical disease in clinic. The clinical mortality is as high as 30%-40%. At present, there is no specific treatment. Erythropoietin (EPO), also known as erythrocyte- stimulating factor, erythropoietin, has a certain amount in normal human body, mainly synthesized by liver in infants and kidneys in adults, which can stimulate erythropoiesis. In recent years, more and more studies have shown that high-dose exogenous EPO administration has benefit effects on multi-organ protection. Therefore, we designed this prospective, double-blind, placebo-controlled trial for defecting EPO on the alveolar fluid clearance of ARDS. The study mainly answers the following questions: Does human erythropoietin accelerate the resolution of alveolar edema in ARDS? Is there any effect on hospital survival? The study will draw conclusions by comparing the control group with the experimental group.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Second Affiliated Hospital of Wenzhou Medical University
Treatments:
Epoetin Alfa
Criteria
Inclusion Criteria:

- Age≥18 years;

- Meeting diagnostic criteria for sepsis 3.0;

- Tracheal intubation and mechanical ventilation;

- Meeting the diagnostic criteria of ARDS Berlin;

- Willing to accept treatment and sign an informed consent form;

Exclusion Criteria:

- Age <18 years;

- Pregnancy or lactation;

- Patients with malignant tumors;

- Recombinant human erythropoietin (rhEPO) allergic patients;

- Hemoglobin (Hb) ≥120g/L;

- have recently taken rhEPO (within 3 months) or participated in other clinical trials;

- History of thromboembolic disease (pulmonary embolism, heart attack, cerebral
infarction, arteriovenous thrombosis);

- Inability or unwillingness to provide informed consent or to comply with the
requirements of the study;